Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?
Authors
Howell, AnthonyAffiliation
Cancer Research UK, Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, United Kingdom.Issue Date
2006
Metadata
Show full item recordCitation
Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator? 2006, 16 Suppl 2:521-3 Int. J. Gynecol. CancerJournal
International Journal of Gynecological CancerDOI
10.1111/j.1525-1438.2006.00686.xPubMed ID
17010063Type
ArticleLanguage
enISSN
1048-891Xae974a485f413a2113503eed53cd6c53
10.1111/j.1525-1438.2006.00686.x
Scopus Count
Collections
Related articles
- Clinical value of fulvestrant in breast cancer.
- Authors: Gradishar WJ
- Issue date: 2005 Apr
- Fulvestrant ('Faslodex'): current and future role in breast cancer management.
- Authors: Howell A
- Issue date: 2006 Mar
- Selective oestrogen receptor downregulator.
- Authors: Howell A
- Issue date: 2002 Nov
- Clinical development of fulvestrant ("Faslodex").
- Authors: Howell A, Abram P
- Issue date: 2005
- Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
- Authors: Safra T, Greenberg J, Ron IG, Ben-Yosef R, Inbar M, Sarid D, Yaal-Hahoshen N
- Issue date: 2008 May